1. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder;Visser;Pediatrics,2007
2. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents;Wolraich;Pediatrics,2011
3. The changing prevalence of attention deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000–2007;Schubert;Dtsch Arztebl Int,2010
4. Movement disorders and dopaminomimetic stimulant drugs;Factor,2005
5. Committee on Medicinal Products for Human Use (CHMP). Elements recommended for inclusion in Summaries of Product Characteristics for methylphenidate-containing medicinal products authorised for the treatment of ADHD in children aged six years and above and adolescents. 2009. Available at: www.ema.europa.eu (accessed 03 Jun 2015).